Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Benzinga · 07/01 15:02
Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.